BIOLOGICAL · Unmapped registry intervention
Nivolumab
Find medicine records ·
Find other trials using this name
Clinical trial
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT03906071
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Sitravatinib
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Mirati Therapeutics Inc.lead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03906071 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.